Lu sur :https://www.ncbi.nlm.nih.gov/pubmed/29943694
[ligne][/ligne]
Traduction disponible directement en cliquant en bas à droite de ce message sur l'expression Traduire en
Il n'y a pas de résumé => Pas de traduction via Google trad par URL, vous devrez faire un copier/coller si Yandex ne suffit pas
[ligne][/ligne]
A la fin de ce message vous trouverez l'article complet en libre diffusion ... Et comme "résumé" le premier paragraphe de ce document ...
Et le document completMyasthenia gravis: the unmet needs of a paradigmatic autoimmune disease
Pedro J Modrego*
Department of Neurology, Hospital Miguel Servet, Isabel la catolica 1–3. Zaragoza -50009, Spain
*Author for correspondence: Fax: + 34 976 491 817; pmodrego@salud.aragon.es
PMID: 29943694 DOI:10.2217/nmt-2018-0014
Although new developments have arisen in the immunopathology and treatment of myasthenia gravis (MG) in the last decade, there are still many unmet needs.
The origin of immunogenicity is not known, with around 10% of patients being seronegative for the antibodies ACh-R, musk-R and LRP4. Antititin antibodies have been associated to determined forms of MG with clinical and outcome implications.
The role of the thymus and thymectomy warrants further research.
With regard to treatment, monoclonal antibodies such as rituximab and eculizumab seem a reasonable alternative in refractory cases but the level of evidence needs improvement.
MG is a paradigmatic autoimmune disease, of chronic course, with exacerbations and remissions, even in the absence of treatment.
...
Message d' un membre de l'équipe technique |
Nous utilisons des services automatiques de traduction fournis par Yandex ou Google. Soyez vigilant sur le risque de contre-sens inhérent à ce genre d'outils. |
Bonne lecture